Advertisement

Pancreatic Cancer pp 1109-1124 | Cite as

Borderline Resectable Pancreatic Cancer

  • Gauri R. Varadhachary
Reference work entry

Abstract:

It is essential to use rigorous criteria to define resectability which allows accurate pretreatment staging and the development of stage-specific therapy. Tumors of borderline resectability have emerged as a distinct subset with multidetector high quality CT imaging and these patients are at a high risk for margin positive resection. Borderline resectable tumors are defined as those with tumor abutment of ≤180°(≤50%) of the SMA or celiac axis, short segment abutment or encasement of the common hepatic artery typically at the gastroduodenal artery origin, and segmental venous occlusion with sufficient venous flow above and below the occlusion to allow an option for venous reconstruction. Patients whose tumors meet these CT criteria are candidates for preoperative systemic chemotherapy followed by chemoradiation. Patients whose imaging studies show radiographic stability or regression and an improvement in serum tumor markers (CA19–9) may proceed to pancreaticoduodenectomy and may require vascular resection and reconstruction. Prospective clinical trials with well-defined eligibility criteria are necessary to determine the best overall treatment strategy for these patients.

Keywords

Pancreatic Cancer Superior Mesenteric Artery National Comprehensive Cancer Network National Comprehensive Cancer Network Superior Mesenteric Vein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wolff R, Abbruzzese J, Evans D: Neoplasms of the exocrine pancreas. In Bast RC Jr., Pollock, RE Weichselbaum, RR Holland, JF Frei E III, Gansler (eds.). TS Cancer Medicine, 6th ed. Hamilton, ON: American Cancer Society + B.C. Decker, 2003, pp. 1585–1614.Google Scholar
  2. 2.
    Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, et al.: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40(4):549–558.CrossRefPubMedGoogle Scholar
  3. 3.
    Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27(3):324–329.CrossRefPubMedGoogle Scholar
  4. 4.
    Takai S, Satoi S, Toyokawa H, Yanagimoto H, Sugimoto N, Tsuji K, et al.: Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 2003;26(3):243–249.CrossRefPubMedGoogle Scholar
  5. 5.
    Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234(6):758–768.CrossRefPubMedGoogle Scholar
  6. 6.
    Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6):567–579.CrossRefPubMedGoogle Scholar
  7. 7.
    Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J: Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168(6):1439–1443.PubMedGoogle Scholar
  8. 8.
    Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al.: Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035–1046.CrossRefPubMedGoogle Scholar
  9. 9.
    Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, et al.: Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 2008;195(3):318–321.CrossRefPubMedGoogle Scholar
  10. 10.
    Faria SC, Tamm EP, Loyer EM, Szklaruk J, Choi H, Charnsangavej C: Diagnosis and staging of pancreatic tumors. Semin Roentgenol 2004;39(3):397–411.CrossRefPubMedGoogle Scholar
  11. 11.
    Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19–9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24(18):2897–2902.CrossRefPubMedGoogle Scholar
  12. 12.
    Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, et al.: Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167(1):104–111; discussion 11–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhong L, Li L, Yao QY: Preoperative evaluation of pancreaticobiliary tumor using MR multi-imaging techniques. World J Gastroenterol 2005;11(24):3756–3761.PubMedGoogle Scholar
  14. 14.
    Tamm E, Charnsangavej C, Szklaruk J: Advanced 3-D imaging for the evaluation of pancreatic cancer with multidetector CT. Int J Gastrointest Cancer 2001;30(1–2):65–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB: Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88(3):325–337.CrossRefPubMedGoogle Scholar
  16. 16.
    Schmidt J, Fraunhofer S, Fleisch M, Zirngibl H: Is peritoneal cytology a predictor of unresectability in pancreatic carcinoma? Hepatogastroenterology 2004;51(60):1827–1831.PubMedGoogle Scholar
  17. 17.
    Zhao ZW, He JY, Tan G, Wang HJ, Li KJ: Laparoscopy and laparoscopic ultrasonography in judging the resectability of pancreatic head cancer. Hepatobiliary Pancreat Dis Int 2003;2(4):609–611.PubMedGoogle Scholar
  18. 18.
    Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG: Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg 2009;208(1):87–95.CrossRefPubMedGoogle Scholar
  19. 19.
    House MG, Yeo CJ, Cameron JL, Campbell KA, Schulick RD, Leach SD, et al.: Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8(3):280–288.CrossRefPubMedGoogle Scholar
  20. 20.
    Valls C, Andia E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, et al.: Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002;178(4):821–826.PubMedGoogle Scholar
  21. 21.
    Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, et al.: Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003;7(1):118–126; discussion 27–28.CrossRefPubMedGoogle Scholar
  22. 22.
    AJCC: Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.Google Scholar
  23. 23.
    NCCN: national comprehensive cancer network. Washington, PA: Practice Guidelines For Pancreatic Cancer, 2004.Google Scholar
  24. 24.
    Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, et al.: Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999;65(7):618–623; discussion 23–24.PubMedGoogle Scholar
  25. 25.
    Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, et al.: Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000;73(4):212–218.CrossRefPubMedGoogle Scholar
  26. 26.
    Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358(9293):1576–1585.CrossRefPubMedGoogle Scholar
  27. 27.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12):1200–1210.CrossRefPubMedGoogle Scholar
  28. 28.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267–277.CrossRefPubMedGoogle Scholar
  29. 29.
    Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299(9):1019–1026.CrossRefPubMedGoogle Scholar
  30. 30.
    Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C: Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996;21(3):202–206.CrossRefPubMedGoogle Scholar
  31. 31.
    Saldinger PF, Reilly M, Reynolds K, Raptopoulos V, Chuttani R, Steer ML, et al.: Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J Gastrointest Surg 2000;4(3):233–237; discussion 38–39.CrossRefPubMedGoogle Scholar
  32. 32.
    Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al.: Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8(8):935–950.CrossRefPubMedGoogle Scholar
  33. 33.
    Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al.: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206(5):833–846; discussion 46–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al.: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26(21):3496–3502.CrossRefPubMedGoogle Scholar
  35. 35.
    Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, et al.: Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002;20(10):2537–2544.CrossRefPubMedGoogle Scholar
  36. 36.
    Talamonti MS, Small W, Jr., Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al.: A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13(2):150–158.CrossRefPubMedGoogle Scholar
  37. 37.
    Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al.: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26(21):3487–3495.CrossRefPubMedGoogle Scholar
  38. 38.
    White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am 2004;13(4):675–684, ix–x.CrossRefPubMedGoogle Scholar
  39. 39.
    Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al.: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127(11):1335–1339.PubMedGoogle Scholar
  40. 40.
    Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al.: Long-Term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009;16(4): 836–847.Google Scholar
  41. 41.
    Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas 201 patients. Ann Surg 1995;221(6):721–731; discussion 31–33.CrossRefPubMedGoogle Scholar
  42. 42.
    Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10(9):1199–1210; discussion 210–211.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Gauri R. Varadhachary
    • 1
  1. 1.Department of Gastrointestinal Medical OncologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations